News - Chiesi Farmaceutici


Current filters:

Chiesi Farmaceutici

Popular Filters

Six-year follow-up data from Glybera treated patients

Six-year follow-up data from Glybera treated patients


Netherlands-based human gene company uniQure and privately-held Italian drugmaker Chiesi Farmaceutici…

BiotechnologyChiesi FarmaceuticiGlyberaRare diseasesResearchuniQure

Study shows Fostair has comparable efficacy to Seretide in asthma patients

Study shows Fostair has comparable efficacy to Seretide in asthma patients


A study has shown that asthma patients may be switched from Seretide to Fostair at an equivalent or lower…

Chiesi FarmaceuticiFostairGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretideUK

Chiesi Farmaceutici to acquire full ownership of Cornerstone Therapeutics


Privately-held Italian drugmaker Chiesi Farmaceutici and specialty US firm Cornerstone Therapeutics (Nasdaq:…

Chiesi FarmaceuticiCornerstone TherapeuticsMergers & AcquisitionsPharmaceutical

Chiesi expands rare disease portfolio with acquisition


Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Italy's Chiesi gains rights to uniQure's Glybera


Netherlands-based venture capital backed human gene therapy firm uniQure has signed collaboration agreements…

BiotechnologyChiesi FarmaceuticiGlyberaLicensingMergers & AcquisitionsPharmaceuticaluniQure

Italy's Chiesi eyes Russian expansion


Privately held Italian drugmaker Chiesi Farmaceutici is considering a massive expansion into the Russian…

Chiesi FarmaceuticiEuropeGenericsMarkets & MarketingPharmstandardProductionRespiratory and Pulmonary

Italy's Chiesi seeking to take full control of Cornerstone Thera


Shares of USA-based Cornerstone Therapeutics (Nasdaq: CRTX) jumped 19.5% to $6.55 in after-hours trading…

Chiesi FarmaceuticiCornerstone TherapeuticsMergers & AcquisitionsPharmaceutical

Cornerstone Thera gets US rights to Chiesi's Bethkis


USA-based specialty pharma firm Cornerstone Therapeutics Inc. (Nasdaq: CRTX) says it has entered into…

BethkisChiesi FarmaceuticiCornerstone TherapeuticsGenericsLicensingNorth AmericaPharmaceuticalRare diseasesRespiratory and Pulmonary

Chiesi Farmaceutici establishes new Mexico affiliate, views growth


Privately-owned Italian drugmaker Chiesi Farmaceutici says it has recently opened its 25th affiliate,…

Chiesi FarmaceuticiFinancialMarkets & MarketingPharmaceuticalResearchSouth America

Veloxis Pharma in LCP-Tacro deal with Chiesi


Denmark's Veloxis Pharmaceuticals A/S (OMX: VELO) has entered into an exclusive distribution agreement…

Chiesi FarmaceuticiEuropeImmunologicalsLCP-TacroLicensingPharmaceuticaltacrolimusVeloxis Pharmaceuticals

FDA advisory negative on Cornerstone's lixivaptan


The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) last…

BiotechnologyCardio-vascularChiesi FarmaceuticiCornerstone TherapeuticslixivaptanNorth AmericaPharmaceuticalRegulation

Kamada in distribution deal with Chiesi for Europe, Turkey and former CIS countries


Israeli biopharma company Kamada (KMDA: TA) has entered into an exclusive agreement with privately-owned…

alpha-1 antitrypsinChiesi FarmaceuticiEuropeKamadaLicensingPharmaceuticalRare diseases

Chiesi outperforming, with sales rising over three times industry average


Italian drugmaker Chiesi’s commitment to innovation and scientific collaboration continues to deliver…

Chiesi FarmaceuticiFinancialPharmaceuticalResearch

Back to top